Medtronic's Integrated Diabetes System Makes The Grade In UK
This article was originally published in The Gray Sheet
Executive Summary
The United Kingdom’s National Health Service should adopt Medtronic’s MiniMed Paradigm Veo insulin pump/glucose monitor system over rival systems for patients with type 1 diabetes who experience disabling hypoglycemia, the country's National Institute for Health and Care Excellence recommends.
You may also be interested in...
Medtronic Launches Predictive MiniMed 640G Insulin Pump Outside The U.S.
The company touts the system as its latest breakthrough toward the development of an artificial pancreas. It can automatically suspend or resume insulin delivery based on pre-set thresholds.
FDA Approves Animas’ Vibe Linking Insulin Pump With DexCom CGM
The insulin pump is the first FDA-approved device featuring Dexcom’s G4 Platinum sensing technology; it allows patients to see glucose data and administer insulin directly from the pump.
US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios
Forthcoming guidance is expected to describe areas of “low-hanging fruit” and those that are more challenging for use of the expedited pathway, Center for Biologics Evaluation and Research Director Peter Marks said.